We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Demand for Coagulation Testing Driving Global Blood Coagulation Analyzer Market

By LabMedica International staff writers
Posted on 22 Jun 2019
The global blood coagulation analyzer market is projected to grow at a substantial CAGR of 5.9% over the period 2018 to 2023, driven by its increasing scope, product types, and applications.

The demand for coagulation testing, increasing healthcare expenditure, rapid development of hospitals and primary healthcare centers, growing occurrences of lifestyle-related conditions such as diabetes, obesity, and cardiovascular disorders, and developing healthcare infrastructure are other factors aiding the market growth. More...
However, the high cost of devices and presence of alternatives is likely to hamper the growth of the blood coagulation analyzer market.

These are the latest findings of Radiant Insights, Inc. (San Francisco, CA, USA), a market intelligence and consulting firm.

Geographically, North America accounted for the largest share of the global blood coagulation analyzer market in 2015 and will continue to lead the market during the forecast period. The North American market is being driven by increased awareness of blood-related diseases among its people, rising prevalence of CVD and growing usage of coagulation analyzers in the region. The key players contributing to the robust growth of the blood coagulation analyzers market are entering into partnerships, mergers and acquisitions, and joint ventures in order to boost the inorganic growth of the industry.

Related Links:
Radiant Insights, Inc.


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Automatic CLIA Analyzer
Shine i6000
New
Gold Member
Platelet Function Analyzer
PL-12
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.